About us

Our Passion

What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field.

Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines.
Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon).

Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.

Our Mission Statement

Our Conviction

We provide an important contribution to biopharmaceuticals, thereby helping millions of people each day. We are among the best in the industry and set new standards in client focus, individual customized solutions and reliability. This is precisely what the Rentschler brand stands for and we are proud of it. Within just a few years, we have become a leading company in our field. This confirms our ability to perform both now and in future.

Client Benefit

We successfully lead projects for our clients, thus ensuring their competitiveness in the markets. We deliver products according to their needs and timelines. Every project with Rentschler Biopharma is in expert hands. For our clients, the Rentschler Biopharma brand stands for expertise in finding solutions, years of experience, innovation, independence, quality of our associated consulting activities and fastest possible time to market. Thus, we minimize the business risk of our demanding global clientele.

Our Business Objective

We make an essential contribution to the global availability of biopharmaceuticals. We generate sufficient earning power and liquidity, which enables us to remain a solid, family owned, medium-sized company and be able to act independently over the long term.

Management

Dr. Frank Mathias,
Chief Executive Officer
Dr. Ralf Otto,
Chief Operating Officer
Stefan Rampf,
Chief Financial Officer

Short CV

Short CV

Short CV

Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst AG. After that, he became General Manager of the successful and renowned companies Servier Deutschland and Amgen GmbH in Munich. Dr. Frank Mathias was Chief Executive Officer of the Medigene AG from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer taken the responsibility for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies. Since April 1st, 2016 Dr. Frank Mathias has been Chief Executive Officer of Rentschler Biopharma SE.

Dr. Ralf Otto has more than 20 years experience in the biotechnology industry and management consulting. Most recently, he was a Partner at McKinsey & Company and essentially built their bio division over the past five years. He led consulting projects for large, medium and small biopharmaceutical companies as well as various international organizations. Prior to this, for 12 years, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim. As Vice President Biopharma Operations, Dr. Ralf Otto headed the Boehringer site in Fremont, California, USA. He started his industrial career in Laboratory and Project Management Biotechnology at Henkel. Dr. Ralf Otto studied biotechnology at the University of Stuttgart (Germany) and Lund University (Sweden) and also at the German Cancer Research Center in Heidelberg. Since winning the genius biotech award by the state of Baden-Württemberg, in 2001, Dr. Ralf Otto has also supported the development of local emerging biotechnology industries. Since a decade, he holds lectures at the University of Karlsruhe (Germany).

Stefan Rampf studied Business Administration and started his career in the audit area of Ernst & Young in 1991. After 7 years, he moved to TA Triumph-Adler AG where he has held different positions up to Head of Controlling. Subsequently, Stefan Rampf became CFO of Triumph-Adler A-Vi-Tec Group and held the position from 2001 to 2004. He continued his successful carreer as Finance Director at De La Rue Cash Systems GmbH and Volvo Financial Services GmbH. After that, Stefan Rampf joined the company ABL-TECHNIC Entlackung GmbH in 2013 as CFO. During his career he has acquired a wealth of management experience in different areas, including the set up of finance departments as active business partner for both single legal entities as well as larger groups. Since May 1st, 2016 Stefan Rampf has been Chief Financial Officer of Rentschler Biopharma SE.

Facts and Figures

Our company

  • Medium-sized, family owned company
  • Since founded in 1927, the company is owned by the family Rentschler
  • Chairman of the supervisory board is
    Prof. Dr. Nikolaus F. Rentschler
  • Headquarters: Laupheim, Germany
  • Gross area: more than 40,000 m²
  • Biotechnology pioneer
  • Full-service contract supplier
  • Contract development and manufacturing of biopharmaceuticals in mammalian cell culture

For further information please have a look at our press releases and announcements or our company brochure:

Our clients

  • We are the outsourcing partner for more than 100 clients worldwide
  • Small, Mid and Big Pharma and Biotech companies have been working with us
  • We offer reliable and detailed consulting services
  • A significant proportion of our clients relied on us for many years and work together with us on several projects

Our track record

  • Expertise with over 200 different molecules
  • Over 250 batches in active pharmaceutical ingredient manufacturing
  • For about 30 % of our cell culture processes we use continuous mode
  • Successful implementation of single-use bioreactors and single-use materials for protein purification
  • Constant and continuous expansion of capacity in process development, manufacturing and quality control

Partnerships

Strategic Alliance with Leukocare AG

The Alliance of Rentschler Biopharma and Leukocare offers contract development and manufacturing with proven excellence including best-in-class formulation that enables clients to realize the full medical and commercial potential of their products.

Advanced formulation development is considered at every step of the development and manufacturing process to capitalize on the full product potential.

Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma's biopharmaceuticals business. Rentschler Biopharma is the first and only contract development and manufacturing organization to use Leukocare´s patented SPS® formulation Technology (SPS® = Stabilizing and Protecting Solutions).

Strategic Partnership with Rentschler Fill Solutions GmbH

The Strategic Partnership of Rentschler Biopharma and Rentschler Fill Solutions provides new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biopharma's clients.

The partnership unites two centers of excellence for the fast and efficient manufacturing of biopharmaceuticals with the Rentschler commitment to quality.

While the Companies remain independent of one another, Rentschler Fill Solutions serves as exclusive partner for the fill and finish of Rentschler Biopharma's full-service clinical manufacturing projects.

Associations

Rentschler Biopharma is a member of the following associations

Verband Forschender Arzneimittelhersteller e.V.
Verband Forschender Arzneimittelhersteller e.V.
Biotechnologie-Industrie-Organisation Deutschland e.V.
Biotechnologie-Industrie-Organisation Deutschland e.V.
Vereinigung Deutscher Biotechnologie-Unternehmen
Vereinigung Deutscher Biotechnologie-Unternehmen
Gesellschaft für Chemische Technik und Biotechnologie e.V.
Gesellschaft für Chemische Technik und Biotechnologie e.V.
Animal Cell Technology Industrial Platform
Animal Cell Technology Industrial Platform

Quality and Sustainability

Quality is an overall concept of Rentschler Biopharma: Competent consulting in the beginning, followed by the project design up to implementation and reliable production of the drug substance or the drug product. Our manufacturing of active pharmaceutical ingredients in state-of-the-art cGMP facilities meets the highest standards of the biopharmaceutical industry. In order to guarantee this, we have high quality standards on our internal cooperation, on our team.
The quality of our performance and results is ensured by comprehensive quality management and precise and reliable quality control. In doing so, we pay attention to continuous monitoring and the adaptation of our quality standards.
Our goal is to enable you to bring to market as quickly as possible a product with the desired therapeutic effect, at the requested level of quality, and in the amount required.

Not only do we make the highest demands on the quality of our work, but also on our relationship with the environment. In our production, we pay attention not only to significantly reducing our quantities of trash but also using the most energy-efficient appliances. We have also operated our own Combined Heat and Power Plant since 2013 on our corporate premises. This facility enables us to produce up to 80 % of our own power supply. Additional diesel emergency generators allow us to be completely self-sufficient, if necessary. This allows us to ensure that manufacturing processes can go on as usual and maintain the quality of our work even during a power blackout.

In addition to ensuring security of our power supply, the CHP provides sustainable and environmentally friendly heat and steam for our manufacturing facilities, and as a result, we reduce CO2 emissions by approximately 2,500 tons annually.

Milestones in Rentschler's History

1927

Foundation as a pharmaceutical manufacturer

Foundation as a pharmaceutical manufacturer

Foundation as a pharmaceutical manufacturer

1974

Installation of the biotechnology division

Installation of the biotechnology division

Installation of the biotechnology division

1979

Start working with recombinant cell lines

Start working with recombinant cell lines

Start working with recombinant cell lines

1983

World´s first market approval for a natural Interferon-ß (Fiblaferon)

World´s first market approval for a natural Interferon-ß (Fiblaferon)

World´s first market approval for a natural Interferon-ß (Fiblaferon)

1989

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

1997

Entering the business of contract development and manufacturing of biopharmaceuticals

Entering the business of contract development and manufacturing of biopharmaceuticals

Entering the business of contract development and manufacturing of biopharmaceuticals

2006

Foundation of Rentschler Inc.

Foundation of Rentschler Inc.

Foundation of Rentschler Inc.

2008

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

2013

Implementing of own Combined Heat and Power plant

Implementing of own Combined Heat and Power plant

Implementing of own Combined Heat and Power plant

2014

First project with the TurboCell™ technology platform

First project with the TurboCell™ technology platform

First project with the TurboCell™ technology platform

2015

Manufacturing starts in the first 2,000 L single-use bioreactor

Manufacturing starts in the first 2,000 L single-use bioreactor

Manufacturing starts in the first 2,000 L single-use bioreactor

2016

Expansion of manufacturing capacity
2x 3,000 L Twin facility, second 2,000 L single-use bioreactor

Expansion of manufacturing capacity2x 3,000 L Twin facility, second 2,000 L single-use bioreactor

Expansion of manufacturing capacity
2x 3,000 L Twin facility, second 2,000 L single-use bioreactor

2017

Alliance between Rentschler Biopharma and Leukocare
Rentschler Biopharma will acquire a 10 % stake in Leukocare

Alliance between Rentschler Biopharma and LeukocareRentschler Biopharma will acquire a 10 % stake in Leukocare

Alliance between Rentschler Biopharma and Leukocare
Rentschler Biopharma will acquire a 10 % stake in Leukocare

2017

Strategic partnership between Rentschler Biopharma and Rentschler Fill Solutions

Strategic partnership between Rentschler Biopharma and Rentschler Fill Solutions

Strategic partnership between Rentschler Biopharma and Rentschler Fill Solutions